VISCHER advised Anaveon on the deal. Anaveon AG, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor...
Anaveon’s CHF 110 Million Series B Financing Round
Dermavant Sciences’ $200 Million Financing
VISCHER acted as Swiss counsel to Dermavant in the transaction. Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, entered...